As described in the answer of 14 March 2022 to Question 133232, progress towards the target of halving healthcare-associated Gram-negative bloodstream infections (GNBSI) has proved very challenging, in part due to the diverse nature of the underlying causes of these infections. Data on the incidence of these infections in England is published quarterly by the UK Health Security Agency, and is available at the following link:<\/p>
We are currently developing the 2024 to 2029 antimicrobial resistance national action plan. We anticipate that in the delivery of this plan, we will continue to focus on GNBSI, building on lessons learnt over the past five years.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-04-23", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-04-23T15:47:27.15Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-04-15", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Antibiotics: Drug Resistance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, with reference to the Answer of 14 March 2022 to Question 133232 on Antibiotics: Drug Resistance and to the policy paper entitled UK five-year action plan for antimicrobial resistance: 2019 to 2024, published on 24 January 2019, what recent progress her Department has made on halving healthcare-associated Gram-negative blood stream infections.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4488", "label" : {"_value" : "Biography information for Martyn Day"}
}
, "tablingMemberConstituency" : {"_value" : "Linlithgow and East Falkirk"}
, "tablingMemberPrinted" : [{"_value" : "Martyn Day"}
], "uin" : "21728"}
, {"_about" : "http://data.parliament.uk/resources/1686722", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1686722/answer", "answerText" : {"_value" : " The Government takes a cross-governmental, One-Health approach to antimicrobial resistance (AMR) as set out in the UK 5-year National Action Plan for antimicrobial resistance. Through the National Action Plan, activity is delivered across the four nations of the United Kingdom on human health, animal health, food, environment, research, and surveillance. The plan is available at the following link:<\/p> <\/p> https://www.gov.uk/government/publications/uk-5-year-action-plan-for-antimicrobial-resistance-2019-to-2024<\/a><\/p> <\/p> The UK is committed to reducing unnecessary use of antibiotics in animals to reduce the risk of the development and spread of AMR in animals and humans. The recently published UK Veterinary Antimicrobial Resistance and Sales Surveillance report shows that sales of antibiotics in food producing animals are at their lowest ever level, with a 59% reduction since 2014. The report is available at the following link:<\/p> <\/p> https://www.gov.uk/government/publications/veterinary-antimicrobial-resistance-and-sales-surveillance-2022<\/a><\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"}
}
, "answeringMemberConstituency" : {"_value" : "Lewes"}
, "answeringMemberPrinted" : {"_value" : "Maria Caulfield"}
, "dateOfAnswer" : {"_value" : "2024-02-08", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2024-02-08T15:49:47.23Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2024-02-01", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Antibiotics: Drug Resistance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps she is taking with Cabinet colleagues to reduce the potential impact of increased antimicrobial resistance caused by the overuse of antibiotics on industrial farms on human health.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4716", "label" : {"_value" : "Biography information for Ruth Jones"}
}
, "tablingMemberConstituency" : {"_value" : "Newport West"}
, "tablingMemberPrinted" : [{"_value" : "Ruth Jones"}
], "uin" : "12649"}
, {"_about" : "http://data.parliament.uk/resources/1675894", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1675894/answer", "answerText" : {"_value" : " The Government takes a \u2018One-Health\u2019 approach to antimicrobial resistance (AMR) as set out in the \u2018UK 5-year action plan for antimicrobial resistance 2019 to 2024\u2019, which is underpinned by the UK\u2019s 20-year Vision to Contain and Control AMR by 2040. Defra is a co-signatory with the Department of Health and Social Care on the 5-year National Acton Plan (NAP) and 20-year vision on AMR, and Defra leads on delivering the animal, plant and environment elements. The AMR NAP lays out the UK Government\u2019s commitment to reducing unnecessary use of antibiotics in animals to reduce the risk of development and spread of AMR in animals and humans, while safeguarding animal health and welfare. A key component of this plan is to reduce the need for antibiotics, which is achieved through good farm management, biosecurity and disease prevention.<\/p> <\/p> In the UK, we have a well-established antimicrobial use and resistance surveillance programme, which includes monitoring of sales and use of antibiotics in animals as well as routine monitoring of AMR in major food-producing species, healthy pigs and poultry. These surveillance programmes allow us to monitor progress and results are published every year in the UK Veterinary Antibiotic Resistance Sales and Surveillance (UK-VARSS) report.<\/p> <\/p> The recently published UK-VARSS report shows that sales of antibiotics in food-producing animals are at their lowest ever level, with a 59% reduction since 2014. This highlights the success of the UK\u2019s voluntary and collaborative approach between the Government and the farming and veterinary sectors to make sustainable reductions in antibiotic use while ensuring high animal health and welfare. The report also highlights that sales of highest priority, critically important antibiotics have reduced by 82% since 2014 and account for less than half a percent of total sales. This is to ensure that these medically important antibiotics are protected for use in humans.<\/p> <\/p> The newly published third edition of the UK\u2019s One Health report, a joint report from the Veterinary Medicines Directorate and the UK Health and Security Agency, brings together antibiotic use and resistance data for people and animals. Sales of antibiotics in 2019 show that approximately two thirds of antibiotics are used in people while one third are used in animals. This report demonstrates the Government\u2019s One Health approach to tackling AMR to keep antibiotics working in both people and animals.<\/p> <\/p> The UK is now in the process of developing the second five-year NAP, which will run from 2024-2029. This will build on progress made in the 2019-2024 NAP and set out challenging ambitions and actions for the next five years, which will set us on course for achieving our long-term national and international ambitions.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4055", "label" : {"_value" : "Biography information for Sir Mark Spencer"}
}
, "answeringMemberConstituency" : {"_value" : "Sherwood"}
, "answeringMemberPrinted" : {"_value" : "Mark Spencer"}
, "dateOfAnswer" : {"_value" : "2023-12-19", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2023-12-19T11:33:28.427Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "13"}
, "answeringDeptShortName" : {"_value" : "Environment, Food and Rural Affairs"}
, "answeringDeptSortName" : {"_value" : "Environment, Food and Rural Affairs"}
, "date" : {"_value" : "2023-12-06", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Antibiotics: Drug Resistance"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Environment, Food and Rural Affairs, whether his Department is taking steps with Cabinet colleagues to help reduce the risk of antimicrobial resistance in humans arising from the overuse of antibiotics on farms.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4382", "label" : {"_value" : "Biography information for Daniel Zeichner"}
}
, "tablingMemberConstituency" : {"_value" : "Cambridge"}
, "tablingMemberPrinted" : [{"_value" : "Daniel Zeichner"}
], "uin" : "5541"}
, {"_about" : "http://data.parliament.uk/resources/1673197", "AnsweringBody" : [{"_value" : "Department for Environment, Food and Rural Affairs"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1673197/answer", "answerText" : {"_value" : " The Government takes a \u2018One-Health\u2019 approach to antimicrobial resistance (AMR) as set out in the \u2018UK 5-year action plan for antimicrobial resistance 2019 to 2024\u2019<\/a>, which is underpinned by the UK\u2019s 20-year Vision to Contain and Control AMR by 2040 . Defra is a co-signatory with the Department of Health and Social Care on the 5-year National Acton Plan and 20-year vision on AMR, and Defra leads on delivering the animal, plant and environment elements.<\/p> <\/p> The UK is committed to reducing unnecessary use of antibiotics in animals to reduce the risk of development and spread of AMR in animals and humans. In the UK, we have a well-established antimicrobial use and resistance surveillance programme, which includes monitoring of sales and use of antibiotics in animals as well as routine monitoring of AMR in major food-producing species, healthy pigs and poultry. These surveillance programmes allow us to monitor progress and results are published every year in the UK Veterinary Antibiotic Resistance Sales and Surveillance<\/a> (UK-VARSS) report.<\/p> <\/p>
https://www.gov.uk/government/statistics/mrsa-mssa-gram-negative-bacteraemia-and-cdi-quarterly-report/quarterly-epidemiological-commentary-mandatory-gram-negative-bacteraemia-mrsa-mssa-and-c-difficile-infections-data-up-to-october-to-december-2023#epidemiological-analyses-of-gram-negative-bacteraemia-data<\/a><\/p>
Incidence of the three main healthcare-associated GNBSI organisms, E. coli, klebsiella pneumoniae, and pseudomonas aeruginosa, has fluctuated between 2019 and 2024, including a sharp decline in the incidence of E. coli seen during the COVID-19 pandemic. However, overall, the total incidence of healthcare associated GNBSI remains significantly above the target.<\/p>